Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
ARQL's Cash to Debt is ranked higher than
97% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. ARQL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ARQL' s Cash to Debt Range Over the Past 10 Years
Min: 0.92  Med: 13.07 Max: No Debt
Current: No Debt
Equity to Asset 0.71
ARQL's Equity to Asset is ranked higher than
54% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARQL: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ARQL' s Equity to Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.67 Max: 0.93
Current: 0.71
-0.16
0.93
F-Score: 4
Z-Score: -10.00
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -134.34
ARQL's Operating margin (%) is ranked lower than
57% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. ARQL: -134.34 )
Ranked among companies with meaningful Operating margin (%) only.
ARQL' s Operating margin (%) Range Over the Past 10 Years
Min: -790.25  Med: -186.78 Max: -23.41
Current: -134.34
-790.25
-23.41
Net-margin (%) -125.98
ARQL's Net-margin (%) is ranked lower than
57% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. ARQL: -125.98 )
Ranked among companies with meaningful Net-margin (%) only.
ARQL' s Net-margin (%) Range Over the Past 10 Years
Min: -582.35  Med: -149.00 Max: -22.75
Current: -125.98
-582.35
-22.75
ROE (%) -38.91
ARQL's ROE (%) is ranked lower than
56% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. ARQL: -38.91 )
Ranked among companies with meaningful ROE (%) only.
ARQL' s ROE (%) Range Over the Past 10 Years
Min: -141.91  Med: -46.24 Max: -8
Current: -38.91
-141.91
-8
ROA (%) -25.46
ARQL's ROA (%) is ranked higher than
51% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ARQL: -25.46 )
Ranked among companies with meaningful ROA (%) only.
ARQL' s ROA (%) Range Over the Past 10 Years
Min: -43.21  Med: -22.14 Max: -5.43
Current: -25.46
-43.21
-5.43
ROC (Joel Greenblatt) (%) -5976.39
ARQL's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. ARQL: -5976.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARQL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3704.36  Med: -791.71 Max: -100.93
Current: -5976.39
-3704.36
-100.93
Revenue Growth (3Y)(%) -41.50
ARQL's Revenue Growth (3Y)(%) is ranked lower than
83% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ARQL: -41.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARQL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.3  Med: 13.15 Max: 44.2
Current: -41.5
-61.3
44.2
EBITDA Growth (3Y)(%) 26.00
ARQL's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARQL: 26.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARQL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.5  Med: 17.70 Max: 143.8
Current: 26
-45.5
143.8
EPS Growth (3Y)(%) 22.30
ARQL's EPS Growth (3Y)(%) is ranked higher than
79% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARQL: 22.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARQL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.4  Med: -15.00 Max: 119.3
Current: 22.3
-48.4
119.3
» ARQL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ARQL Guru Trades in Q4 2014

First Eagle Investment 4,444,899 sh (+56.31%)
First Eagle Investment 4,444,899 sh (+56.31%)
Jim Simons 1,532,767 sh (+36.85%)
Chuck Royce 200,000 sh (unchged)
» More
Q1 2015

ARQL Guru Trades in Q1 2015

First Eagle Investment 5,719,968 sh (+28.69%)
Jim Simons 1,873,783 sh (+22.25%)
Chuck Royce Sold Out
» More
Q2 2015

ARQL Guru Trades in Q2 2015

First Eagle Investment 8,719,968 sh (+52.45%)
Jim Simons 2,103,655 sh (+12.27%)
First Eagle Investment 8,719,968 sh (+52.45%)
» More
Q3 2015

ARQL Guru Trades in Q3 2015

First Eagle Investment 8,719,968 sh (unchged)
Jim Simons 1,936,544 sh (-7.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Arqule Inc

Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc
Jean-Marie Eveillard recently increased his stakes in biotech company Arqule Inc (NASDAQ:ARQL), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/B 3.28
ARQL's P/B is ranked lower than
63% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ARQL: 3.28 )
Ranked among companies with meaningful P/B only.
ARQL' s P/B Range Over the Past 10 Years
Min: 1.46  Med: 2.85 Max: 111.17
Current: 3.28
1.46
111.17
P/S 9.11
ARQL's P/S is ranked higher than
51% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. ARQL: 9.11 )
Ranked among companies with meaningful P/S only.
ARQL' s P/S Range Over the Past 10 Years
Min: 2.79  Med: 9.56 Max: 102.75
Current: 9.11
2.79
102.75
Current Ratio 3.36
ARQL's Current Ratio is ranked lower than
59% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ARQL: 3.36 )
Ranked among companies with meaningful Current Ratio only.
ARQL' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.35 Max: 12.74
Current: 3.36
1.06
12.74
Quick Ratio 3.36
ARQL's Quick Ratio is ranked lower than
56% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. ARQL: 3.36 )
Ranked among companies with meaningful Quick Ratio only.
ARQL' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.34 Max: 12.74
Current: 3.36
1.06
12.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.35
ARQL's Price/Net Cash is ranked higher than
73% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARQL: 3.35 )
Ranked among companies with meaningful Price/Net Cash only.
ARQL' s Price/Net Cash Range Over the Past 10 Years
Min: 1.47  Med: 4.02 Max: 646
Current: 3.35
1.47
646
Price/Net Current Asset Value 3.35
ARQL's Price/Net Current Asset Value is ranked higher than
74% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. ARQL: 3.35 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARQL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.29  Med: 3.70 Max: 252.5
Current: 3.35
1.29
252.5
Price/Tangible Book 3.28
ARQL's Price/Tangible Book is ranked higher than
65% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ARQL: 3.28 )
Ranked among companies with meaningful Price/Tangible Book only.
ARQL' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.57  Med: 2.56 Max: 95.33
Current: 3.28
0.57
95.33
Price/Median PS Value 0.96
ARQL's Price/Median PS Value is ranked lower than
51% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARQL: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
ARQL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 0.81 Max: 8.42
Current: 0.96
0.08
8.42
Earnings Yield (Greenblatt) (%) -24.30
ARQL's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ARQL: -24.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARQL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -230.1  Med: 0.00 Max: 0
Current: -24.3
-230.1
0

More Statistics

Revenue(Mil) $11
EPS $ -0.23
Beta1.88
Short Percentage of Float1.49%
52-Week Range $1.09 - 2.65
Shares Outstanding(Mil)62.89

Analyst Estimate

Dec15 Dec17 Dec18
Revenue(Mil) 12 14 29
EPS($) -0.33 -0.27 -0.40
EPS without NRI($) -0.33 -0.27 -0.40

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AQL.Germany,
Arqule Inc was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIPTM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
ArQule to Present at Upcoming Investor Conferences Feb 04 2016
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors Jan 28 2016
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of... Jan 25 2016
12 Biotechs With Binary Events Coming This Year Jan 08 2016
ArQule, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 24 2015
ArQule upgraded by RBC Capital Mkts Dec 21 2015
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087 Dec 15 2015
ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087 Dec 15 2015
ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib... Dec 10 2015
ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib... Dec 10 2015
ARQULE INC Financials Dec 08 2015
Do Hedge Funds Love Hugoton Royalty Trust (HGT)? Nov 27 2015
ArQule's Drug Gets Orphan Drug Status for Proteus Syndrome Nov 18 2015
ArQule and the National Human Genome Research Institute of the National Institutes of Health... Nov 17 2015
UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference Nov 09 2015
ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference Nov 09 2015
Edited Transcript of ARQL earnings conference call or presentation 4-Nov-15 2:00pm GMT Nov 04 2015
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2015
ArQule Reports Third Quarter 2015 Financial Results Nov 04 2015
ArQule reports 3Q loss Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK